PMC Links for Books (Select 2824216) - PMC

Result Filters

Links from Books

Items: 19

Select item 104146951.

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

Margret Merino, Yvette Kasamon, Marc Theoret, Richard Pazdur, Paul Kluetz, Nicole Gormley

J Clin Oncol. 2023 May 20; 41(15): 2706–2712. Published online 2023 Mar 17. doi: 10.1200/JCO.23.00225

Correction in:: J Clin Oncol. 2023 Aug 9 : JCO2301583.

PMCID:: PMC10414695

Article PDF–213K

Select item 103050872.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open label, randomised, phase 3 trial

Robert J Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T Bourlon, Amishi Y Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher M Hocking, Elizabeth R Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burcin Simsek, Christian Scheffold, Andrea B Apolo, Toni K Choueiri

Lancet Oncol. Author manuscript; available in PMC 2023 Jul 1.

Published in final edited form as: Lancet Oncol. 2022 Jul; 23(7): 888–898. Published online 2022 Jun 7. doi: 10.1016/S1470-2045(22)00290-X

Correction in:: Lancet Oncol. 2022 Jul; 23(7): e319.

Correction in:: Lancet Oncol. 2022 Sep; 23(9): e404.

PMCID:: PMC10305087

Abstract Article PDF–851K

Select item 102841183.

Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K. Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C. Goh, Masatoshi Eto, Lee Bennett, Jinyi Wang, Jie Janice Pan, Todd L. Saretsky, Rodolfo F. Perini, Cixin Steven He, Kalgi Mody, David Cella

Lancet Oncol. Author manuscript; available in PMC 2023 Jun 21.

Published in final edited form as: Lancet Oncol. 2022 Jun; 23(6): 768–780. Published online 2022 Apr 27. doi: 10.1016/S1470-2045(22)00212-1

PMCID:: PMC10284118

Abstract Article PDF–1.8M

Select item 102596214.

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): results from a double-blind, randomised, phase 3 trial

Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C Goh, Dingwei Ye, Alejo Lingua, Jean-Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vázquez Estévez, Burcin Simsek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex

Lancet. Author manuscript; available in PMC 2024 Mar 11.

Published in final edited form as: Lancet. 2023 Mar 11; 401(10379): 821–832. Published online 2023 Feb 9. doi: 10.1016/S0140-6736(22)02574-0

PMCID:: PMC10259621

Abstract Article PDF–1.0M

Select item 84365915.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T.K. Choueiri, T. Powles, M. Burotto, B. Escudier, M.T. Bourlon, B. Zurawski, V.M. Oyervides Juárez, J.J. Hsieh, U. Basso, A.Y. Shah, C. Suárez, A. Hamzaj, J.C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J.P. Feregrino, J. Żołnierek, D. Pook, E.R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M.A. Maurer, B. Simsek, F. Ejzykowicz, G.M. Schwab, A.B. Apolo, R.J. Motzer, CheckMate 9ER Investigators

N Engl J Med. Author manuscript; available in PMC 2021 Sep 13.

Published in final edited form as: N Engl J Med. 2021 Mar 4; 384(9): 829–841. doi: 10.1056/NEJMoa2026982

PMCID:: PMC8436591

Abstract Article PDF–767K

Select item 67166036.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John Haanen, Brian Rini, Laurence Albiges, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Negrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Jr., Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, Boris Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri

N Engl J Med. Author manuscript; available in PMC 2019 Sep 21.

Published in final edited form as: N Engl J Med. 2019 Mar 21; 380(12): 1103–1115. Published online 2019 Feb 16. doi: 10.1056/NEJMoa1816047

PMCID:: PMC6716603

Abstract Article PDF–721K

Select item 60574797.

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel George, Michael J. Morris

Eur J Cancer. Author manuscript; available in PMC 2018 Jul 24.

Published in final edited form as: Eur J Cancer. 2018 May; 94: 115–125. Published online 2018 Mar 20. doi: 10.1016/j.ejca.2018.02.012

Correction in:: Eur J Cancer. 2018 Nov; 103: 287.

PMCID:: PMC6057479

Abstract Article PDF–504K

Select item 59725498.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R.J. Motzer, N.M. Tannir, D.F. McDermott, O. Arén Frontera, B. Melichar, T.K. Choueiri, E.R. Plimack, P. Barthélémy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C.K. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M.-O. Grimm, S. Bracarda, C.H. Barrios, Y. Tomita, D. Castellano, B.I. Rini, A.C. Chen, S. Mekan, M.B. McHenry, M. Wind-Rotolo, J. Doan, P. Sharma, H.J. Hammers, B. Escudier, for the CheckMate 214 Investigators

N Engl J Med. Author manuscript; available in PMC 2018 Oct 5.

Published in final edited form as: N Engl J Med. 2018 Apr 5; 378(14): 1277–1290. Published online 2018 Mar 21. doi: 10.1056/NEJMoa1712126

PMCID:: PMC5972549

Abstract Article PDF–403K

Select item 59432509.

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri

Br J Cancer. 2018 May 1; 118(9): 1176–1178. Published online 2018 Mar 26. doi: 10.1038/s41416-018-0061-6

PMCID:: PMC5943250

Abstract Article PDF–404K

Select item 571948710.

Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma

Robert J. Motzer, Bernard Escudier, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma, on behalf of the CheckMate 025 investigators.

N Engl J Med. Author manuscript; available in PMC 2017 Dec 7.

Published in final edited form as: N Engl J Med. 2015 Nov 5; 373(19): 1803–1813. Published online 2015 Sep 25. doi: 10.1056/NEJMoa1510665

PMCID:: PMC5719487

Abstract Article PDF–1.1M

Select item 556967711.

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Thomas E. Hutson

J Clin Oncol. 2013 Oct 20; 31(30): 3791–3799. Published online 2013 Sep 9. doi: 10.1200/JCO.2012.47.4940

PMCID:: PMC5569677

Abstract Article PDF–197K

Select item 549835812.

Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis

Hiten D. Patel, Phillip M. Pierorazio, Michael H. Johnson, Ritu Sharma, Emmanuel Iyoha, Mohamad E. Allaf, Eric B. Bass, Stephen M. Sozio

Clin J Am Soc Nephrol. 2017 Jul 7; 12(7): 1057–1069. Published online 2017 May 8. doi: 10.2215/CJN.11941116

PMCID:: PMC5498358

Abstract Article

Select item 545580713.

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara K. Walsh, Darren R. Feldman, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Daniel J. George, Michael J. Morris

J Clin Oncol. 2017 Feb 20; 35(6): 591–597. Published online 2016 Nov 14. doi: 10.1200/JCO.2016.70.7398

Correction in:: J Clin Oncol. 2017 Nov 10; 35(32): 3736.

Correction in:: J Clin Oncol. 2018 Feb 10; 36(5): 521.

PMCID:: PMC5455807

Abstract Article PDF–1.1M

Select item 502453914.

Cabozantinib versus everolimus in advanced renal cell carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles, Paul Mainwaring, Brian I. Rini, Frede Donskov, Hans Hammers, Thomas E. Hutson, Jae-Lyun Lee, Katriina Peltola, Bruce J. Roth, Georg A. Bjarnason, Lajos Géczi, Bhumsuk Keam, Pablo Moroto, Daniel Y. C. Heng, Manuela Schmidinger, Philip W. Kantoff, Anne Borgman, Colin Hessel, Christian Scheffold, Gisela M. Schwab, Nizar M. Tannir, Robert J. Motzer, for the METEOR Investigators

N Engl J Med. Author manuscript; available in PMC 2016 Sep 15.

Published in final edited form as: N Engl J Med. 2015 Nov 5; 373(19): 1814–1823. Published online 2015 Sep 25. doi: 10.1056/NEJMoa1510016

PMCID:: PMC5024539

Abstract Article PDF–544K

Select item 480678215.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim A. Margolin, Elizabeth R. Plimack, Alexandre M. Lambert, Ian M. Waxman, Hans J. Hammers

J Clin Oncol. 2015 May 1; 33(13): 1430–1437. Published online 2014 Dec 1. doi: 10.1200/JCO.2014.59.0703

PMCID:: PMC4806782

Abstract Article PDF–258K

Select item 364630716.

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Roberto Pili, Georg A. Bjarnason, Xavier Garcia-del-Muro, Jeffrey A. Sosman, Ewa Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin

J Clin Oncol. 2009 Aug 1; 27(22): 3584–3590. Published online 2009 Jun 1. doi: 10.1200/JCO.2008.20.1293

PMCID:: PMC3646307

Abstract Article PDF–188K

Select item 265107417.

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice Dutcher, Eric J. Small

J Clin Oncol. 2008 Nov 20; 26(33): 5422–5428. Published online 2008 Oct 20. doi: 10.1200/JCO.2008.16.9847

PMCID:: PMC2651074

Abstract Article PDF–143K

Select item 257043118.

Risk Score and Metastasectomy Independently Impact Prognosis in Patients with Recurrent Renal Cell Carcinoma

Scott E Eggener, Ofer Yossepowitch, Shilajit Kundu, Robert J Motzer, Paul Russo

J Urol. Author manuscript; available in PMC 2009 Sep 1.

Published in final edited form as: J Urol. 2008 Sep; 180(3): 873–878. Published online 2008 Jul 17. doi: 10.1016/j.juro.2008.05.006

PMCID:: PMC2570431

Abstract Article PDF–1.6M

Select item 227532419.

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James C. Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg

N Engl J Med. Author manuscript; available in PMC 2008 Mar 26.

Published in final edited form as: N Engl J Med. 2003 Jul 31; 349(5): 427–434. doi: 10.1056/NEJMoa021491